Ligand Pharmaceuticals Incorporated — Company profile
Healthcare · Biotechnology · United States
Last price 318.97 USD (Nov 2, 2026, 10:54 AM EST) · Market cap 6.38B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Details
| Name | Ligand Pharmaceuticals Incorporated |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 47 |
| Founded | 1987 |
| Ipo Date | 1992-11-18 |
| Ceo | Todd Davis |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US53220K5048 |
| Cusip | 53220K504 |
| Cik | 0000886163 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Todd C. Davis Ph.D. | Chief Executive Officer and Director |
| Octavio Espinoza | Chief Financial Officer |
| Andrew T. Reardon J.D. | Chief Legal Officer and Secretary |
| Paul J. Hadden | Senior Vice President of Investments and Business Development |
| Melanie J. Herman CPA | Executive Director of Investor Relations and Financial Planning and Analysis |
| Marjorie Fackovec | Head of People Operations |
| Dr. Keith Marschke Ph.D. | Senior Vice President of Biology and Scientific Affairs |
| Dr. Vincent D. Antle Ph.D. | Senior Vice President of Technical Operations and QA - Capitsol |
| Dr. Karen R. Reeves M.D. | Senior Vice President of Investments and Head of Clinical Strategy |
| Richard B. Baxter | Senior Vice President of Investment Operations |
Contact
| Address | 555 Heritage Drive, Suite 200, Jupiter, Florida 33458, United States |
| Phone | 858 550 7500 |
| Website | https://www.ligand.com |